AUG 21, 2013 5:00 PM PDT

Global penetration of genomic-like techniques into fast clinical diagnostics of infective diseases in emergency: applicability and technological bottle-necks?

Speaker
  • Head of Molecular Microbiology Unit- Molecular Biology, Jewish General Hospital - McGill University

Abstract

Dr Ivan Brukner entered into genomic era back in 1989 (ex-Yugoslavia), trying to describe and solve repeating sequence "branching motif problem" in building whole genome sequence. Next 5-10 years, his research was targeting sequence-dependent DNA structural problems, where contradictory puzzle about origin of DNA curvature and bending (crystallographic versus soft biochemistry data) was resolved (Italy, Germany and Canada). In 2000-2007, focus was directed toward design of nucleic-acid-based "ideal" point of care diagnostic device. Robust, multiplex, hybridization-based diagnostic device (which operates at standard "room" temperatures - in spite of ~90% sequence cross-similarity) was constructed and functionally tested. The universal protocol for selection of "robust" hybridization probes was result of this adventure. After joining Jewish General Hospital in Montreal (~2009), his work was becoming more clinically applicable, focusing on high volume molecular assays with strong financial and/or diagnostic impact (MRSA, C.difficile, VRE). He realized the strong need for applicability of new molecular techniques in emergency, including NGS, and definition of technological bottlenecks is subject of his talk in this secession.    


Show Resources
You May Also Like
SEP 10, 2020 9:00 AM PDT
C.E. CREDITS
SEP 10, 2020 9:00 AM PDT
Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
SEP 03, 2020 9:00 AM PDT
C.E. CREDITS
SEP 03, 2020 9:00 AM PDT
DATE: September 3, 2020 TIME: 09:00am PT, 12:00pm ET xxx Learning Objectives: xxx Webinars will be available for unlimited on-demand viewing after live event. LabRoots is approved as a provi...
C.E. CREDITS
This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
JUN 17, 2020 1:30 PM PDT
C.E. CREDITS
JUN 17, 2020 1:30 PM PDT
Understanding the complex interplay between a pathogen and the host response is important to developing effective vaccines and therapeutics. The nCounter® Analysis System and GeoMx®...
NOV 16, 2020 8:00 AM PST
C.E. CREDITS
NOV 16, 2020 8:00 AM PST
Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
NOV 18, 2020 8:00 AM PST
C.E. CREDITS
NOV 18, 2020 8:00 AM PST
DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
Loading Comments...
Show Resources
Attendees
  • See more